Main Products/ Services/ Pipelines & Platforms
OBI Pharma, Inc., is a Taiwan biopharmaceutical company publicly-listed on the Taipei Exchange (TPex ticker: 4174). OBI’s mission is to develop and license novel therapeutic agents for unmet medical needs of cancer patients. OBI holds proprietary ADC platform technologies and has a novel oncology portfolio: ADC platform technonogies - GlycOBI™ - ThiOBI™ Novel cancer therapeutics - Adagloxad Simolenin (formerly OBI-822; Globo H cancer vaccine) - OBI-833 (Globo H cancer vaccine) - OBI-3424 (small-molecule prodrug targeting AKR1C3 enzyme) - OBI-992 (TROP2 ADC, ThiOBI platform) - OBI-902 (TROP2 ADC, GlycOBI platform) - OBI-904 (Nectin4 ADC, GlycOBI platform) - OBI-905 (HER2 ADC, GlycOBI platform)
Business Interests
ADC platform technologies - OBI is looking for collaborative R&D and out-license opportunities to create first- or best-in-class ADCs. OBI’s novel cancer therapeutics – OBI is seeking out-licensing opportunities to expedite the clinical development of our pipeline products.
Contact Info
Kevin Poulos
Chief Commercial Officer
(619) 537-7698 ext. 102
kpoulos@obipharmausa.com